# Neo-clerodane Diterpenes from the Hallucinogenic Sage *Salvia divinorum*

Osamu Shirota,* Kumi Nagamatsu, and Setsuko Sekita

*Laboratory of Pharmacognosy and Natural Product Chemistry, Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki-City, Kagawa 769-2193, Japan*

*Received September 15, 2006*

Seven new neo-clerodane diterpenes, salvidivins A (**2**), B, (**3**), C (**4**), and D (**5**), salvinorins H (**6**) and I (**7**), and divinorin F (**8**), along with eight known neo-clerodane diterpenes, salvinorins A (**1**)−F, divinatorins A and B, and seven other constituents, were isolated from the hallucinogenic sage *Salvia divinorum*. The structures of **1**−**7** were elucidated on the basis of 2D NMR spectroscopic studies.

The Mexican hallucinogenic sage *Salvia divinorum* Epling & Játiva (Laminaceae), which is called "diviner's sage" or "magic mint", contains the neo-clerodane diterpene salvinorin A (**1**) as a hallucinogenic active constituent.[1,2] Recently, due to an increase in the popularity of this hallucinogenic plant as a recreational drug, a number of countries have begun to regulate either or both *S. divinorum* and salvinorin A (**1**) as controlled substances.[3] Salvinorin A (**1**) is a potent naturally occurring non-nitrogenous $\kappa$-opioid selective agonist, and hence it is considered to be of interest for the development of novel therapeutic agents for Alzheimer's disease.[4] After the hallucinogenic actions of **1** were revealed, several research groups have studied *S. divinorum* and the salvinorins, and this has resulted in an increasing number of reports on the isolation and synthesis of new neo-clerodane diterpenes during the past few years.[5−18] Recently, two new neo-clerodane diterpenes, salvinicins A and B, were isolated from this same plant material, and it was demonstrated that salvinicin A is a partial $\kappa$-opioid agonist, whereas salvinicin B is the first $\mu$-opioid antagonist having a neo-clerodane skeleton.[19,20] Such research reports have shown further possibilities for the use of *S. divinorum* as a resource for new bioactive compounds, and this encouraged us to attempt the isolation of new salvinorin-like diterpenoids from this hallucinogenic sage. Herein, we report a study on the isolation and structure determination of the new compounds **1**−**7** from this plant.

## Results and Discussion

A dichloromethane-soluble portion (72 g) of the methanol extract (123 g) of the commercially available dried leaves (970 g) of *S. divinorum* was subjected to silica gel open-column chromatography using an *n*-hexane−ethyl acetate solvent mixture to afford 12 fractions. The fractions, which showed pink to purple spots on silica gel TLC using a vanillin−phosphoric acid reagent, were further separated by ODS-medium-pressure liquid chromatography (MPLC) using aqueous methanol as elution solvent. These additional fractions were then applied repeatedly to ODS-HPLC using aqueous acetonitrile as elution solvent to yield seven new neo-clerodane diterpenes, named salvidivins A (**2**), B (**3**), C (**4**), and D (**5**), salvinorins H (**6**) and I (**7**), and divinorin F (**8**). In addition to these substances, eight known neo-clerodane diterpenes, salvinorins A (**1**)−F[1,2,5,7] and divinatorins A and B,[6] as well as six other constituents that have not been reported from this plant, nepetoidin B,[21,22] dehydrovomifoliol,[23] isololiolide,[24] methyl caffate, methyl 3,4-dihydroxybenzoate, and 3,4-dihydroxybenzaldehyde, along with a previously reported compound, loliolide,[25] were also isolated. The structures of these known compounds were identified by comparison with their published data or with commercially available compounds.

Compounds **2** and **3** gave pseudomolecular ion peaks at *m/z* 465.1789 and 465.1765 $[M + H]^+$, respectively, in the HRESIMS, suggesting a molecular formula of $C_{23}H_{29}O_{10}$ in each case. The solubility of both compounds in several deuterated solvents such as $CDCl_3$, $CD_3OD$, and pyridine-$d_5$ was low, and the $^1H$ NMR spectra measured in DMSO-$d_6$ showed broadened peaks. Therefore, the NMR spectra for their structure elucidation were measured in $CDCl_3$−$CD_3OD$ (ca. 1:1) mixtures. Even in this solvent mixture, some of the peaks were broadened in both the $^1H$ and $^{13}C$ NMR spectra, especially in the olefinic regions. Comparison of the $^1H$ and $^{13}C$ NMR spectra of **2** and **3** with those of salvinorin A (**1**) suggested that these compounds are structurally similar. In fact, the chemical shift assignments for the A and B rings, and their respective substituents of **2** and **3**, could be assigned readily by comparison to **1**; this was confirmed by analysis of the HMBC spectrum, as shown in Figure 1. The biggest problem with both the $^1H$ and $^{13}C$ NMR spectra of **2** and **3** was that the signals that should have been assignable to the furan ring of **1** were extremely broad. Only one of the four carbon signals assignable to a furan ring unit of **2** appeared as a peak at $\delta_C$ 171.4 in the $^{13}C$ NMR spectrum. In the HSQC spectrum of **2**, a broad methine proton signal at $\delta_H$ 6.10 showed a cross-peak with a broad carbon signal that appeared at $\delta_C$ 117.8, and another broad signal at $\delta_H$ 6.18 exhibited a cross-peak with an extremely broad signal at around $\delta_C$ 98. Also in the HMBC spectrum of **2** a cross-peak was observed between one methylene proton of C-11 at $\delta_H$ 1.68 and an extremely broad carbon signal at around $\delta_C$ 167.5. In the case of **3**, all four carbon signals corresponding to the furan ring unit could not be observed as discrete peaks. In the HSQC spectrum of **3**, a broad methine proton at $\delta_H$ 7.20 showed a cross-peak with a broad carbon signal that appeared around $\delta_C$ 147.5. On the other hand, in the HMBC spectrum of **3**, the H-12 methine proton at $\delta_H$ 5.40 showed cross-peaks with broad carbon signals around $\delta_C$ 136, 147.5, and 170. However, the remaining extremely broad carbon signal at around $\delta_C$ 98 did not exhibit any cross-peaks. Although only limited information could be obtained for the furan derivative moieties of **2** and **3**, the signals around $\delta_C$ 170 were assigned to carbonyl carbons. Further, a quaternary carbon at C-13 ($\delta_C$ 167.5 for **2**, $\delta_C$ 136 for **3**) suggested one double bond in the moiety, and the remaining carbon signal around $\delta_C$ 98 could be assigned to a hemiacetal. From the HMBC correlations depicted in Figure 1, the structures of **2** and **3** were assigned as shown. Therefore, it is concluded that the furan derivative moieties of both **2** and **3** represent a pair of geometrical isomers of the $\gamma$-hydroxy-$\alpha,\beta$-unsaturated $\gamma$-lactone, which differ from each other at the linkage position to C-12; **2** is linked at the $\beta$-position, whereas **3** is linked at the $\alpha$-position from the carbonyl carbon of the lactone. The relative configuration of **2** and **3** was determined by ROESY NMR correlations, as shown in Figure 1, except for the hemiacetal proton,

* To whom correspondence should be addressed. Tel: +81-87-894-5111. Fax: +81-87-894-0181. E-mail: shirota@kph.bunri-u.ac.jp.

10.1021/np060456f CCC: $33.50 © 2006 American Chemical Society and American Society of Pharmacognosy
Published on Web 11/17/2006

**Chart 1**



which did not result in any informative cross-peaks. Thus, structures **2** and **3**, respectively, were proposed for salvidivins A and B.

Compounds **4** and **5** were confirmed to have the same molecular formula as **2** and **3**, respectively, by measurement of their HRESIMS data. Their NMR spectra obtained in $CD_3OD$ showed essentially the same pattern; further, **4** and **5** showed differences in the chemical shifts in the low-field region in both their $^1H$ and $^{13}C$ NMR spectra. In the $^1H$ NMR spectra, one set of *trans* olefinic protons ($\delta_H$ 6.33, 6.50, $J = 16.3$ Hz for **4**; $\delta_H$ 6.13, 6.72, $J = 16.2$ Hz for **5**) was observed, and these were assigned as protons of a double bond between C-11 and C-12 since HMBC correlations were observed with C-8, C-9, C-10, and C-20. These olefinic protons also had HMBC correlations with carbons at $\delta_C$ 99.9 and 164.3 for **4** and at $\delta_C$ 133, 144.5, and 172.1 for **5**, as shown in Figure 2; these carbons were assigned as furan ring resonances connected to C-12. Further, HMBC NMR spectroscopic analysis revealed the presence of the same $\gamma$-hydroxy-$\alpha,\beta$-unsaturated $\gamma$-lactone moiety in **2** and **3**. The HMBC spectrum of **5** also confirmed a C-17 carboxylic acid group instead of the lactone ring in the case of **1**–**3**, whereas the HMBC spectrum of **4** failed to give long-range correlations from any proton to a carbon at $\delta_C$ 172.6 assigned to C-17. Similar to the ROESY NMR spectra of **2** and **3**, the ROESY spectra of **4** and **5** revealed the same relative configuration for the A and B rings as **1**, as shown in Figure 2. From these data, the structures of **4** and **5** were determined for salvidivins C and D, respectively. In the $^1H$ NMR spectrum of **4**, H-10 had a split peak, and broad signals of H-8 and H-12 were observed. H-12 showed ROESY correlations with H-14, H-16, and H-20, whereas H-11 exhibited correlations with H-8, H-10, H-14, H-16, and H-20 in the ROESY spectrum of **4**. These observations suggested that rotational conformers with respect to bonds between C-9 and C-11 and between C-12 and C-13 are evident. A similar consideration also applied to **5**, in which both H-11 and H-12 showed ROESY correlations with H-8, H-10, H-14, and H-20. The same applied to **2** and **3**, which showed broad signals around the $\gamma$-lactone moiety.

Compound **6** gave a pseudomolecular ion peak at *m/z* of 391.1779 $[M + H]^+$ in the HRESIMS, suggesting a molecular formula of $C_{21}H_{27}O_7$. In the $^1H$ NMR spectrum, four olefinic protons, of which three were a pair of normal furan rings as in **1**, an absence of acetyl methyl protons, and one additional oxymethine proton were assigned by a general comparison with **1**. Moreover, in the $^{13}C$ NMR spectrum, the absence of a carbonyl carbon, which was assignable to C-1, and the appearance of one additional double bond were evident by comparison with **1**. Further, observations from the HMBC and ROESY NMR spectra, shown in Figure 3, supported the structure of **6** as salvinorin H, which is the deacetylated derivative of salvinorins C–E.[5,7]

Compound **7** showed pseudomolecular ion peaks at *m/z* 807.3 $[2M + Na]^+$ and 415.2 $[M + Na]^+$ in the ESIMS and a peak at *m/z* 415.1783 $[M + Na]^+$ in the HRESIMS, suggesting a molecular formula of $C_{21}H_{28}O_7$. In the $^1H$ NMR spectrum, the appearance of two oxymethine protons assignable to H-1 and H-2 and four olefinic protons assignable to a furan ring and the H-3 methine resembled those of **6** fairly closely. One oxymethine proton assignable to H-12 was shifted upfield and one additional oxymethine appeared at $\delta_H$ 4.72, in contrast to **6**. The additional oxymethine signal was finally assigned as H-17, since HMBC correlations were observed between the oxymethine proton and C-8, and C-9 and between the oxymethine carbon at $\delta_C$ 95.5 and H-8, as shown in Figure 3. Therefore, it was concluded that the lactone ring in **6** is partially reduced to a cyclic acetal in the case of **7**. The relative stereochemistry of the acetal hydroxyl group was assigned with $\beta$-orientation since ROESY NMR correlations were observed between H-12,



**Figure 1.** Principal HMBC and ROESY correlations of **2** and **3**.



**Figure 2.** Principal HMBC and ROESY correlations of **4** and **5**.




**Figure 3.** Principal HMBC and ROESY correlations of **6**−**8**.

H-17, and H-20. On the basis of these data, the structure **7** was proposed for salvinorin I.

Compound **8** was assigned a molecular formula of $C_{21}H_{30}O_6$, as suggested from the pseudomolecular ion peaks at *m/z* of 779.4 $[2M + Na]^+$ and 401.2 $[M + Na]^+$ in the ESIMS and a peak at *m/z* of 401.1952 $[M + Na]^+$ in the HRESIMS. In the $^1H$ NMR spectrum, the appearance of two oxymethine protons assignable to H-1 and H-2 and four olefinic protons assignable to a furan ring and H-3 methines closely resembled those of **6** and **7**, although one set of oxymethylene protons was observed instead of the disappearance of the H-12 oxymethine proton. A detailed HMBC spectroscopic analysis led to the conclusion that **8** is a divinatorin-type neo-clerodane diterpene that possesses a decalin ring and a furan ring without a lactone ring.[6,12] ROESY NMR spectroscopic analyses confirmed the relative stereochemistry of this isolate. Consequently, the structure **8** was proposed for divinatorin F.

In conclusion, seven new neo-clerodane diterpenes have been isolated from commercially available *S. divinorum*. Salvidivins A (**2**), B (**3**), C (**4**), and D (**5**) are unique neo-clerodane diterpenes that possess a $\gamma$-hydroxy-$\alpha$,$\beta$-unsaturated $\gamma$-lactone moiety, and the pairs **2** and **3**, and **4** and **5**, respectively, are geometrical isomers at the $\gamma$-lactone moiety. It appears that **2** and **3** are important precursors of salvinicins A and B; salvinicin A is described as being a partial agonist of the $\kappa$-opioid receptor, whereas salvinicin B is reported to be the first $\mu$-opioid antagonist having a neo-clerodane skeleton.[19,20] Salvinorin H (**6**) has a 1,2-dihydroxy substitution on the A ring. The occurrence of salvinorin H (**6**) was predicted previously;[13] this is because similar salvinorins acetylated at C-1 (salvinorin D), at C-2 (salvinorin E), or at both sites (salvinorin C) have already been isolated from *S. divinorum*.[5,7] Salvinorin I (**7**) is a derivative of **6**, which is partially reduced at C-17, while divinatorin F (**8**) seems to be a precursor of **6**; these three substances have the same A, B ring substitution pattern in their molecules. It would be interesting to ascertain whether or not any of these new compounds also exhibit agonist/antagonist activities against various types of opioid receptors.

## Experimental Section

**General Experimental Procedures.** Melting points were determined on a Yanaco MP-J3 micro melting point apparatus and are uncorrected. Optical rotations were measured with a JASCO P-1030 polarimeter. UV, CD, and IR spectra were obtained with a JASCO V-560 UV/vis spectrophotometer, a JASCO J-820 spectropolarimeter, and a JASCO FT/IR-6300 spectrometer with ATR option, respectively. 1D and 2D $^1H$ and $^{13}C$ NMR spectra were recorded on a Varian Unity INOVA 500 spectrometer at 300 K using Varian standard pulse sequences. Phase-sensitive ROESY experiments were conducted with a mixing time of 300 ms. A 3.57 ms (140 Hz) delay was used to optimize one-bond coupling in the HSQC spectra and suppress it in the HMBC spectra, and the evolution delay for long-range couplings in the HMBC spectra was set to 62.5 ms (8 Hz). ESITOFMS and HRESITOFMS were obtained on a Q-TOF micro-mass spectrometer (Micromass/Waters). Silica gel open-column chromatography was performed on silica gel 60 (Merck). Medium-pressure liquid chromatography (MPLC)

**Table 1.** $^1H$ NMR (500 MHz) and $^{13}C$ NMR (125 MHz) Spectroscopic Data for **2** and **3**

| | salvidivin A (**2**) in $CDCl_3$−$CD_3OD$, 1:1 | | salvidivin B (**3**) in $CDCl_3$−$CD_3OD$, 1:1 | |
|---|---|---|---|---|
| position | $\delta_C$, mult. | $\delta_H$, mult. (*J* in Hz) | $\delta_C$, mult. | $\delta_H$, mult. (*J* in Hz) |
| 1 | 203.4, qC | | 203.4, qC | |
| 2 | 76.0, CH | 5.20, dd (7.3, 12.2) | 76.0, CH | 5.20, dd (7.6, 12.5) |
| 3 | 31.3, $CH_2$ | 2.27, q-like (13.2) | 31.4, $CH_2$ | 2.25, q-like (12.9) |
| | | 2.34, ddd (3.9,7.6, 13.2) | | 2.31,[d] dt (3.7, 7.6) |
| 4 | 53.6, CH | 2.90, dd (3.7, 13.2) | 53.6, CH | 2.92, dd (3.7, 13.2) |
| 5 | 42.6 | | 42.6, qC | |
| 6 | 38.3, $CH_2$ | 1.68,[c] br-t (12.5) | 35.9, $CH_2$ | 1.68,[c] br-t (12.2) |
| | | 1.79, br-dd (2.9, 10.0) | | 1.79, br-dt (3.1, 13.1) |
| 7 | 18.7, $CH_2$ | 1.62, br-dt (2.9, 13.2) | 18.7, $CH_2$ | 1.61, br-dt (3.5, 13.3) |
| | | 2.12, br-d (10.5) | | 2.12, br-dd (3.2, 13.7) |
| 8 | 51.2,[a] CH | 2.36, br-dd (2.7, 11.5) | 51.1, CH | 2.35,[d] br-dd (3.4, 10.5) |
| 9 | 35.9,[a] qC | | 38.4, qC | |
| 10 | 63.4, CH | 2.45,[d] s | 63.5, CH | 2.47, s |
| 11 | 41.0,[a] $CH_2$ | 1.68,[c] br-t (12.5) | 40.6, $CH_2$ | 1.68,[c] br-t (12.2) |
| | | 2.45,[d] br-s | | 2.46, dd (5.7, 13.4) |
| 12 | 73.9,[a] CH | 5.49, br-s | 72.6,[a] CH | 5.40, dd (5.7, 11.8) |
| 13 | 167.5,[b] qC | | 136,[b] qC | |
| 14 | 117.8,[a] CH | 6.10, br-s | 147.5,[b] CH | 7.20, br-s |
| 15 | 171.4, qC | | 98,[b] qC | 6.18, br-s |
| 16 | 98,[b] CH | 6.18, br-s | 170,[b] CH | |
| 17 | 172.1, qC | | 172.6, qC | |
| 18 | 172.8, qC | | 172.9, qC | |
| 19 | 16.7, $CH_3$ | 1.11, s | 16.6, $CH_3$ | 1.10, s |
| 20 | 15.3,[a] $CH_3$ | 1.43, s | 15.2, $CH_3$ | 1.43, s |
| O*C*OCH3 (2) | 171.2, qC | | 171.0, qC | |
| OCO*CH3* (2) | 20.7, $CH_3$ | 2.18, s | 20.6, $CH_3$ | 2.15, s |
| COO*CH3* (4) | 52.3, $CH_3$ | 3.74, s | 52.2, $CH_3$ | 3.73, s |

[a] Carbon signal appeared as a broad signal. [b] Carbon signal extremely broad or did not appear clearly; chemical shift value determined from HSQC and/or HMBC spectra. [c] Signals superimposed on each other. [d] Assignments may be exchanged with each other.

**Table 2.** $^{1}$H NMR (500 MHz) and $^{13}$C NMR (125 MHz) Spectroscopic Data for **4** and **5**

| | salvidivin C (**4**) in $CD_3OD$ | | salvidivin D (**5**) in $CD_3OD$ | |
|---|---|---|---|---|
| position | $\delta_C$, mult. | $\delta_H$, mult. ($J$ in Hz) | $\delta_C$, mult. | $\delta_H$, mult. ($J$ in Hz) |
| 1 | 203.9, qC | | 203.9, qC | |
| 2 | 77.0, CH | 5.19, dd (71, 12.2) | 76.9, CH | 5.20, dd (7.2, 12.6) |
| 3 | 32.2, $CH_2$ | 2.15, q-like (13.0) | 32.2, $CH_2$ | 2.15, q-like (12.9) |
| | | 2.29, ddd (3.5, 7.2, 13.1) | | 2.28, ddd (3.5, 7.2, 12.9) |
| 4 | 54.1,[a] CH | 3.01, dd (3.4, 13.4) | 54.0, CH | 3.02, dd (3.5, 13.3) |
| 5 | 43.6, qC | | 43.4, qC | |
| 6 | 38.8, $CH_2$ | 1.73,[a] m | 38.8, $CH_2$ | 1.72, br-d (7.3) |
| | | 1.73,[a] m | | 1.72, br-d (7.3) |
| 7 | 22.0, $CH_2$ | 1.78, br-ddd (3.2, 3.4, 11.1) | 22.1, $CH_2$ | 1.75, br-dd (3.4, 13.4) |
| | | 1.95, br-ddt (5.9, 12.5, 12.7) | | 1.94, m |
| 8 | 54.1,[a] CH | 2.42, br-s | 54.2, CH | 2.41, dd (2.9, 12.5) |
| 9 | 42.5, qC | | 42.1, qC | |
| 10 | 61.6, CH 61.3, CH | 2.81, 2.87, br-s | 61.7, CH | 2.81, s |
| 11 | 152.6, CH | 6.50, d (16.3) | 147.5, CH | 6.72, d (16.2) |
| 12 | 120.4, CH | 6.33, br-d (16.3) | 118.2, CH | 6.13, d (16.2) |
| 13 | 164.3, qC | | 133.0, qC | |
| 14 | 116.5, CH | 5.92, s | 144.5, CH | 7.03, s |
| 15 | 173.7,[b] qC | | 98.4, CH | 6.04, br-s |
| 16 | 99.9, CH | 6.13, s | 172.1, qC | |
| 17 | 176.2, qC | | 176.3, qC | |
| 18 | 173.6,[b] qC | | 173.7, qC | |
| 19 | 16.4, $CH_3$ | 1.05, s | 16.5, $CH_3$ | 1.06, s |
| 20 | 15.9, $CH_3$ | 1.56, s | 15.8, $CH_3$ | 1.55, s |
| O*C*O$CH_3$ (2) | 171.6, qC | | 171.5, qC | |
| OCO*$CH_3$* (2) | 20.5, $CH_3$ | 2.09, s | 20.5, $CH_3$ | 2.08, s |
| COO*$CH_3$* (4) | 52.2, $CH_3$ | 3.70, s | 52.2, $CH_3$ | 3.70, s |

[a] Signals superimposed on each other. [b] Assignments may be exchanged with each other.

**Table 3.** $^{1}$H NMR (500 MHz) and $^{13}$C NMR (125 MHz) Spectroscopic Data for **6**−**8**

| | salvinorin H (**6**) in $CDCl_3$−$CD_3OD$ = 1:1 | | salvinorin I (**7**) in $CD_3OD$ | | divinatorin F (**8**) in $CDCl_3$ | |
|---|---|---|---|---|---|---|
| position | $\delta_C$, mult. | $\delta_H$, mult. ($J$ in Hz) | $\delta_C$ | $\delta_H$, mult. ($J$ in Hz) | $\delta_C$ | $\delta_H$, mult. ($J$ in Hz) |
| 1 | 66.1, CH | 4.25, d (4.9) | 66.5, CH | 4.22, d (4.8) | 66.3, CH | 4.30, d (4.6) |
| 2 | 70.3, CH | 4.17, dd (2.2, 4.9) | 71.1, CH | 4.14, dd (2.2, 4.8) | 70.0, CH | 4.24, dd (2.3, 4.8) |
| 3 | 138.1, CH | 6.49, d (2.2) | 138.6, CH | 6.45,[b] d (2.2) | 135.3, CH | 6.45, d (2.3) |
| 4 | 141.9, qC | | 142.7, qC | | 143.0, qC | |
| 5 | 38.3,[a] qC | | 39.2, qC | | 38.0, qC | |
| 6 | 37.7, $CH_2$ | 1.18, dt (3.4, 13.2) | 39.3, $CH_2$ | 1.13, br-dt (1.1, 8.6) | 37.7, $CH_2$ | 1.15, dt (3.5, 12.9) |
| | | 2.44, dt (3.4, 13.2) | | 2.39, dt (3.4, 12.9) | | 2.32, dt (3.3, 12.9) |
| 7 | 19.3, $CH_2$ | 1.77, br-dq (2.8, 13.5) | 19.4, $CH_2$ | 1.53, dq (3.4, 13.4) | 21.8, $CH_2$ | 1.54, dq (3.4, 12.9) |
| | | 2.00, br-dq (3.4, 14.4) | | 1.78, dq (3.4, 13.5) | | 1.85, m |
| 8 | 52.2, CH | 2.44, br-dd (2.7, 12.2) | 54.7, CH | 1.19, br-dt (2.2, 5.8) | 44.5, CH | 1.60, m |
| 9 | 38.2,[a] qC | | 38.3, qC | | 38.8, qC | |
| 10 | 54.5, CH | 1.28, br-s | 56.2, CH | 1.16, br-s | 48.1, CH | 1.42, br-s |
| 11 | 44.6, $CH_2$ | 1.69, br-d (10.3) | 46.9, $CH_2$ | 1.26, br-t (12.1) | 38.9, $CH_2$ | 1.78, br-dt (4.4, 12.7) |
| | | 2.51, dd (6.1, 13.2) | | 1.95, dd (3.2, 12.1) | | 1.88, br-dt (5.1, 15.1) |
| 12 | 73.3, CH | 5.63, dd (5.9, 11.0) | 67.6, CH | 4.98, dd (2.3, 11.6) | 18.3, $CH_2$ | 2.07, br-dt (4.7, 13.5) |
| | | | | | | 4.84, br-dt (4.2, 13.5) |
| 13 | 126.8, qC | | 128.7, qC | | 124.8, qC | |
| 14 | 109.3, CH | 6.47, d (1.5) | 110.1, CH | 6.46,[b] t (0.9) | 110.9, CH | 6.25, d (0.7) |
| 15 | 144.7, CH | 7.45, d (1.7) | 144.1, CH | 7.42, t (1.6) | 142.9, CH | 7.34, d (1.6) |
| 16 | 140.6, CH | 7.52, t (0.7) | 140.4, CH | 7.48, d (0.7) | 138.5, CH | 7.20, s |
| 17 | 174.5, qC | | 95.5, CH | 4.72, d (9.0) | 63.9, $CH_2$ | 3.38, dd (8.1, 10.5) |
| | | | | | | 3.83, dd (3.7, 10.5) |
| 18 | 168.1, qC | | 168.5, qC | | 167.1, qC | |
| 19 | 22.2, $CH_3$ | 1.68, s | 22.8, $CH_3$ | 1.68, s | 21.9, $CH_3$ | 1.65, s |
| 20 | 16.4, $CH_3$ | 1.44, s | 16.5, $CH_3$ | 1.45, s | 21.2, $CH_3$ | 1.18, s |
| COO*$CH_3$* (4) | 51.9, $CH_3$ | 3.69, s | 51.9, $CH_3$ | 3.69, s | 51.6, $CH_3$ | 3.72, s |

[a] Assignments may be exchanged with each other. [b] Signals superimposed on each other.

was performed with a prepacked glass column (Ultra Pack: 26 mm i.d. × 300 mm for medium-scale separation, 50 mm i.d. × 300 mm for large-scale separation; Yamazen Corporation, Kyoto, Japan) packed with 50 $\mu$m octadecyl silica gel (ODS). HPLC was performed with an Inertsil PREP-ODS column (6 mm i.d. × 250 mm for analysis, 20 mm i.d. × 250 mm for preparative; GL Science Inc., Tokyo, Japan) packed with 10 $\mu$m ODS. TLC was conducted on precoated silica gel 60 $F_{254}$ (Merck) and/or RP-18 $F_{254s}$ (Merck), and the spots were detected by heating after spraying with vanillin−phosphoric acid reagent.

**Plant Material.** Dried *S. divinorum* leaves were purchased in June 2005 from Ethnogens.com (Lawrence, KS). Voucher specimens were deposited at the Medicinal Herbarium, Faculty of Pharmaceutical Sciences at Kagawa campus, Tokushima Bunri University, specimen # 050601-001.

**Extraction and Isolation.** Commercial dried *S. divinorum* leaves (970 g) were powdered and extracted with MeOH three times around 40 to 50 °C, and the MeOH solution was evaporated in vacuo under 40 °C to yield a MeOH extract (123 g). The extract was partitioned between $CH_2Cl_2$ and water three times and evaporated to give a $CH_2Cl_2$-soluble portion (72 g). The $CH_2Cl_2$-soluble portion was then chromatographed over a silica gel open column (0.6 kg; 50 × 540 mm) eluted with an *n*-hexane−EtOAc gradient solvent system (10:0, 8:2, 1:1, 0:10, then MeOH) to yield 12 fractions. Fraction (Fr.) numbers 4 to 10 showed pink to purple spots by TLC (*n*-hexane−

EtOAc, 1:1) by spraying with vanillin−phosphoric acid spray reagent. The positive fractions were separated by ODS MPLC with aqueous MeOH as elution solvent. The MPLC-derived fractions were further purified by ODS HPLC with aqueous acetonitrile as elution solvent to yield seven new compounds: salvidivins A (**2**, 85 mg) and B (**3**, 80 mg) from Fr. 5−8 eluted with 35% acetonitrile; salvidivins C (**4**, 41 mg) and D (**5**, 42 mg) from Fr. 5 eluted with 33% acetonitrile; salvinorin H (**6**, 120 mg) from Fr. 5−7 eluted with 35% acetonitrile; and salvinorin I (**7**, 6.5 mg) and divinorin F (**8**, 15 mg) from Fr. 5 eluted with 33% and 35% acetonitrile, respectively. The known salvinorins A (**1**, 2.0 g), B (37 mg), C (176 mg), D (180 mg), E (28 mg), and F (100 mg) and divinatorins A (219 mg) and B (29 mg) were also isolated from Fr. 4−10. Along with them, seven other known constituents, nepetoidin B (15 mg), dehydrovomifoliol (1.5 mg), isololiolide (5.4 mg), methyl caffeate (11 mg), methyl 3,4-dihydroxybenzoate (2.9 mg), 3,4-dihydroxybenzaldehyde (2.7 mg), and loliolide (26 mg), were isolated from Fr. 4−10.

**Salvidivin A (2):** amorphous solid; mp 217−222 °C; $[\alpha]^{24}_{D}$ −69.6 (*c* 0.28, $CHCl_3$); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 206 (4.07), 253 (sh, 2.88) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 292 (−1.6), 225 (−3.9) nm; IR (ATR) 3324, 2932, 1725, 1456, 1376, 1277, 1230, 1198, 1165, 1134, 1083, 1048, 951, 893, 861, 783, 688, 605 $cm^{-1}$; $^1H$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 500 MHz) and $^{13}C$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 125 MHz), see Table 1; ESITOFMS *m/z* 929.4 (15, $[2M + H]^+$), 465.2 (7, $[M + H]^+$), 447.2 (100, $[M - H_2O]^+$); HRESITOFMS *m/z* 465.1789 (calcd for $C_{23}H_{29}O_{10}$, 465.1761).

**Salvidivin B (3):** amorphous solid; mp 216−221 °C; $[\alpha]^{24}_{D}$ −54.2 (*c* 0.28, MeOH); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 203.5 (3.92), 248 (sh, 3.15) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 291.5 (−1.9), 222 (−4.4) nm; IR (ATR) 3462, 2955, 1772, 1729, 1702, 1456, 1378, 1276, 1210, 1164, 1147, 1092, 1048, 1005, 935, 886, 770 $cm^{-1}$; $^1H$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 500 MHz) and $^{13}C$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 125 MHz), see Table 1; ESITOFMS *m/z* 929.4 (55, $[2M + H]^+$), 465.2 (17, $[M + H]^+$), 387.1 (100, $[M - H_2O - CO_2Me]^+$); HRESITOFMS *m/z* 465.1765 (calcd for $C_{23}H_{29}O_{10}$, 465.1761).

**Salvidivin C (4):** amorphous solid; mp 123−127 °C; $[\alpha]^{22}_{D}$ −133.3 (*c* 0.22, $CHCl_3$); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 269 (3.93) nm; CD (MeOH) $\lambda_{max}$ nm ($\Delta\epsilon$) 303 (0.2), 266.5 (−3.3), 226 (1.4); IR (ATR) 2953, 1717, 1645, 1437, 1375, 1234, 1169, 1126, 1048, 948, 889, 772 $cm^{-1}$; $^1H$ NMR ($CD_3OD$, 500 MHz) and $^{13}C$ NMR ($CD_3OD$, 125 MHz), see Table 1; ESITOFMS *m/z* 929.4 (15, $[2M + H]^+$), 465.2 (14, $[M + H]^+$), 447.2 (100, $[M - H_2O]^+$); HRESITOFMS *m/z* 465.1765 (calcd for $C_{23}H_{29}O_{10}$, 465.1761).

**Salvidivin D (5):** amorphous solid; mp 185−193 °C; $[\alpha]^{24}_{D}$ −107.2 (*c* 0.27, MeOH); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 261 (3.95) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 261.5 (−3.2), 225 (−3.6) nm; IR (ATR) 3381, 2953, 1770, 1729, 1705, 1684, 1438, 1384, 1340, 1281, 1225, 1082, 1009, 928, 774, 662 $cm^{-1}$; $^1H$ NMR ($CD_3OD$, 500 MHz) and $^{13}C$ NMR ($CD_3OD$, 125 MHz), see Table 1; ESITOFMS *m/z* 929.4 (2, $[2M + H]^+$), 465.2 (12, $[M + H]^+$), 387.1 (100, $[M - H_2O - CO_2Me]^+$); HRESITOFMS *m/z* 465.1772 (calcd for $C_{23}H_{29}O_{10}$, 465.1761).

**Salvinorin H (6):** amorphous solid; mp 95−103 °C; $[\alpha]^{22}_{D}$ 29.1 (*c* 0.22, $CHCl_3$); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 209.5 (4.03) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 257.5 (−1.5), 228 (7.0), 203.5 (−8.6) nm; IR (ATR) 3444, 2952, 1715, 1507, 1435, 1375, 1314, 1225, 1142, 1071, 1026, 949, 875, 787, 686, 601 $cm^{-1}$; $^1H$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 500 MHz) and $^{13}C$ NMR ($CDCl_3$−$CD_3OD$, 1:1, 125 MHz), see Table 2; ESITOFMS *m/z* 391.2 (42, $[M + H]^+$), 373.2 (100, $[M - H_2O]^+$); HRESITOFMS *m/z* 391.1779 (calcd for $C_{21}H_{27}O_7$, 391.1757).

**Salvinorin I (7):** amorphous solid; mp 217−220 °C; $[\alpha]^{22}_{D}$ −4.2 (*c* 0.11, MeOH); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 210.5 (3.99) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 258.5 (−1.1), 228 (9.2), 203 (−6.9) nm; IR (ATR) 3400, 2945, 1692, 1541, 1507, 1438, 1240, 1174, 1130, 1085, 1039, 1022, 1000, 968, 875, 808, 684, 602 $cm^{-1}$; $^1H$ NMR ($CD_3OD$, 500 MHz) and $^{13}C$ NMR ($CD_3OD$, 125 MHz), see Table 2; ESITOFMS *m/z* 807.3, (30, $[2M + Na]^+$), 415.2 (32, $[M + Na]^+$), 375.2 (22, $[M - H_2O]^+$), 255.1 (100); HRESITOFMS *m/z* 415.1783 (calcd for $C_{21}H_{28}O_7Na$, 415.1733).

**Divinatorin F (8):** amorphous solid; mp 97−99 °C; $[\alpha]^{23}_{D}$ 8.4 (*c* 0.12, MeOH); UV (MeOH) $\lambda_{max}$ (log $\epsilon$) 213 (3.99) nm; CD (MeOH) $\lambda_{max}$ ($\Delta\epsilon$) 260.5 (−0.9), 227.5 (10.2), 202 (−8.9) nm; IR (ATR) 3395, 2928, 2878, 1704, 1434, 1226, 1164, 1055, 1026, 1007, 873, 777, 600 $cm^{-1}$; $^1H$ NMR ($CDCl_3$, 500 MHz) and $^{13}C$ NMR ($CDCl_3$, 125 MHz), see Table 2; ESITOFMS *m/z* 779.4, (18, $[2M + Na]^+$), 401.2 (45, $[M + Na]^+$), 343.2 (61), 311.2 (100); HRESITOFMS *m/z* 401.1952 (calcd for $C_{21}H_{30}O_6Na$, 401.1940).

**Acknowledgment.** This work was supported in part by research grants from Research on Regulatory Science of Pharmaceuticals and Medical Devices, H16-iyaku-060 (to O.S.) and H16-iyaku-030 (to S.S.), from the Ministry of Health, Labour and Welfare, Japan.

## References and Notes

(1) Ortega, A.; Blount, J. F.; Manchand, P. S. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2505−2508.
(2) Valdes, L. J., III; Butler, W. M.; Hatfield, G. M.; Paul, A. G.; Koreeda, M. *J. Org. Chem.* **1984**, *49*, 4716−4720.
(3) Giroud, C.; Felber, F.; Augsburger, M.; Horisberger, B.; Rivier, L.; Mangin, P. *Forensic Sci. Int.* **2000**, *112*, 143−150.
(4) Sheffler, D. J.; Roth, B. L. *Trends Pharmacol. Sci.* **2003**, *24*, 107−109.
(5) Valdes, L. J., III; Chang, H.-M.; Visger, D. C.; Koreeda, M. *Org. Lett.* **2001**, *3*, 3935−3937.
(6) Bigham, A. K.; Munro, T. A.; Rizzacasa, M. A.; Robins-Browne, R. M. *J. Nat. Prod.* **2003**, *66*, 1242−1244.
(7) Munro, T. A.; Rizzacasa, M. A. *J. Nat. Prod.* **2003**, *66*, 703−705.
(8) Beguin, C.; Richards, M. R.; Wang, Y.; Chen, Y.; Liu-Chen, L.-Y.; Ma, Z.; Lee, D. Y. W.; Carlezon, W. A.; Cohen, B. M. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 2761−2765.
(9) Harding, W. W.; Tidgewell, K.; Byrd, N.; Cobb, H.; Dersch, C. M.; Butelman, E. R.; Rothman, R. B.; Prisinzano, T. E. *J. Med. Chem.* **2005**, *48*, 4765−4771.
(10) Lee, D. Y. W.; He, M.; Kondaveti, L.; Liu-Chen, L.-Y.; Ma, Z.; Wang, Y.; Chen, Y.; Li, J.-G.; Beguin, C.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4169−4173.
(11) Lee, D. Y. W.; Karnati, V. V. R.; He, M.; Liu-Chen, L.-Y.; Kondaveti, L.; Ma, Z.; Wang, Y.; Chen, Y.; Beguin, C.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3744−3747.
(12) Lee, D. Y. W.; Ma, Z.; Liu-Chen, L.-Y.; Wang, Y.; Chen, Y.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem.* **2005**, *13*, 5635−5639.
(13) Munro, T. A.; Goetchius, G. W.; Roth, B. L.; Vortherms, T. A.; Rizzacasa, M. A. *J. Org. Chem.* **2005**, *70*, 10057−10061.
(14) Munro, T. A.; Rizzacasa, M. A.; Roth, B. L.; Toth, B. A.; Yan, F. *J. Med. Chem.* **2005**, *48*, 345−348.
(15) Beguin, C.; Richards, M. R.; Li, J.-G.; Wang, Y.; Xu, W.; Liu-Chen, L.-Y.; Carlezon, W. A.; Cohen, B. M. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4679−4685.
(16) Harding, W. W.; Schmidt, M.; Tidgewell, K.; Kannan, P.; Holden, K. G.; Dersch, C. M.; Rothman, R. B.; Prisinzano, T. E. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 3170−3174.
(17) Lee, D. Y. W.; He, M.; Liu-Chen, L.-Y.; Wang, Y.; Li, J.-G.; Xu, W.; Ma, Z.; Carlezon, W. A.; Cohen, B. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5498−5502.
(18) Tidgewell, K.; Harding, W. W.; Lozama, A.; Cobb, H.; Shah, K.; Kannan, P.; Dersch, C. M.; Parrish, D.; Deschamps, J. R.; Rothman, R. B.; Prisinzano, T. E. *J. Nat. Prod.* **2006**, *69*, 914−918.
(19) Harding, W. W.; Tidgewell, K.; Schmidt, M.; Shah, K.; Dersch, C. M.; Snyder, J.; Parrish, D.; Deschamps, J. R.; Rothman, R. B.; Prisinzano, T. E. *Org. Lett.* **2005**, *7*, 3017−3020.
(20) Harding, W. W.; Schmidt, M.; Tidgewell, K.; Kannan, P.; Holden, K. G.; Gilmour, B.; Navarro, H.; Rothman, R. B.; Prisinzano, T. E. *J. Nat. Prod.* **2006**, *69*, 107−112.
(21) Nakanishi, T.; Nishi, M.; Inada, A.; Obata, H.; Tanabe, N.; Abe, S.; Wakashiro, M. *Chem. Pharm. Bull.* **1990**, *38*, 1772−1774.
(22) Grayer, R. J.; Eckert, M. R.; Veitch, N. C.; Kite, G. C.; Marin, P. D.; Kokubun, T.; Simmonds, M. S. J.; Paton, A. J. *Phytochemistry* **2003**, *64*, 519−528.
(23) Kato, T.; Tsunakawa, M.; Sasaki, N.; Aizawa, H.; Fujita, K.; Kitahara, Y.; Takahashi, N. *Phytochemistry* **1977**, *16*, 45−48.
(24) Mori, K.; Khlebnikov, V. *Liebigs Ann. Chem.* **1993**, 77−82.
(25) Valdes, L. J., III. *J. Nat. Prod.* **1986**, *49*, 171.

NP060456F